Wee1 Inhibitor Toxicity Linked to Early DNA Replication Role
A newly identified function for the cancer drug target Wee1 in healthy cells may explain the severe side effects that have disrupted clinical trials, researchers reported in October 2026. While Wee1 has long been known as a late-stage cell cycle brake, a study published in Nature reveals that the enzyme also helps normal cells begin copying their DNA much earlier in the cycle. This discovery challenges established scientific models and provides a potential pathway for designing safer cancer therapies.
Cell Cycle Safeguards and Mutation Vulnerabilities
In roughly half of all human cancers, the tumor-suppressor protein p53 is inactive, robbing cells of their primary mechanism for halting division when DNA damage occurs. These mutated cancers grow dependent on a secondary safeguard: Wee1, an enzyme that acts as a backup brake preventing damaged cells from dividing. Drugs designed to block Wee1 seek to exploit this specific vulnerability, but clinical adoption has been affected by serious adverse effects in patients.
Researchers from the MRC Laboratory of Medical Sciences (LMS), the University of Oxford, and UCL set out to investigate why these inhibitors cause such high toxicity. They built a mathematical model based on existing scientific literature to predict cellular responses to Wee1 inhibition. However, laboratory experiments on healthy and cancerous cells contradicted the literature-based predictions.
Protein Degradation Complex Disruption in Normal Tissues
The experimental results showed that Wee1 controls a protein degradation complex responsible for breaking down molecules needed for DNA replication. By switching off this complex early in the cell cycle, Wee1 permits DNA copying to start. When Wee1 is blocked by inhibitors, the complex remains active, which delays or halts normal cell progression.
We think what’s happening in patients is that when they’re being treated with these Wee1 inhibitors, it’s stopping their normal fast proliferating cells, like you get in the colon and the blood system, from starting to replicate,
said Alexis, head of the Cell Cycle Control group at the LMS. And so those cells are stuck, unable to generate new cells, and that could be causing some of the toxic side effects.
Targeted Treatment Refinements and Preclinical Testing
The findings suggest that clinicians might use this new understanding to match Wee1 inhibitors with cancers that have reduced activity in the targeted protein degradation complex. This approach could establish a therapeutic window, allowing lower doses to eliminate cancer cells while sparing healthy tissues from severe toxicity.
The research team, whose study was funded by the Medical Research Council and Cancer Research UK, is now planning to test these predictions in preclinical models and in patients currently enrolled in Wee1 inhibitor clinical trials. Investigators also aim to explore whether alternative methods of inhibiting Wee1 can bypass its early cell cycle functions entirely.